A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

Abstract

We evaluate the application of surfactant-free liquid-phase exfoliated MoS₂ nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody–antigen based recognition element. Employing antigen–antibody binding, we increased the probability of the endocytosis of MoS₂ nanosheets into CAIX expressing cells by 30%. The nanosheets are functionalized with a specific antibody M75, which forms an antigen–antibody complex with CAIX. The bioconjugation of MoS₂ nanosheets involves biocompatible components with low cytotoxicity, verified in the tested cell lines by fluorescence-based cell viability assay. The cellular internalization is quantified by flow cytometry, while the internalization is confirmed by label-free confocal Raman imaging. Raman measurements show increased lysosomal activity in the proximity of the internalized nanoplatforms.